Explore the potential of gene therapy as a groundbreaking approach to curing diseases, beyond traditional pharmacological ...

Leading RNA drug developer Suzhou Ribo Life Science Co. Ltd. passed its hearing for a listing on the Hong Kong Stock Exchange, marking the official launch of its IPO, according to its post-hearing ...

Ministeerri Fayyaa Itoophiyaa damee fayyaa biyyattii jabeessuuf mootummaa Ameerika waliin waliigaltee deeggarsaa doolaara ...

VESALIUS-CV was big in 2025, but studies looking at triglycerides, CRISPR, and oral GLP-1s also made the highlight reel.

Nonclinical protocol study design accepted by FDA Study to commence in First Quarter 2026King of Prussia, Pennsylvania--(Newsfile Corp. - December 23, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) ...

Nonclinical protocol study design accepted by FDA Study to commence in First Quarter 2026King of Prussia, ...

TheFly reported on December  16 that Oppenheimer raised its price target on WVE to $32 from $24 while maintaining an ...

Alnylam's $250 million investment will enhance its Norton, Massachusetts facility with an enzymatic ligation platform to meet ...

Veritas In Silico Inc. ( ($JP:130A) ) has issued an update. Veritas In Silico has filed a substance patent application in Japan for a ...

Hawaasa Afrikaa Kibbaa Afrikaanars Tiraamp ofitti fudhachuu fedhan maaltu kakaase? 'BBC Africa Eye' qorateera.

Dexoligo Therapeutics has presented data for their liver-targeted siRNA DXO-1801 for the potential treatment of inflammation-driven anemia, a serious complication of chronic diseases such as chronic ...

PeptiDream (TSE:4587) just logged two meaningful scientific wins, advancing an oral dual IL 17 program into its clinical portfolio and hitting a preclinical siRNA delivery milestone with Alnylam, ...